~~<i id='5173078957'><strike id='5173078957'><tt id='5173078957'><pre id='5173078957'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-09-27 23:54:26 Page View：51318

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： An outdated Medicare rule harms dementia patients with anxiety
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

leisure time

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Take antibiotics after sex, CDC recommends for certain risk groups

AdobeTheCentersforDiseaseControlandPreventionfinalizeditsguidelinesforpost-exposureprophylaxisagains

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

BD to buy Edwards patient monitoring unit for $4.2 billion

IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness